CN104997767A - Pharmaceutical composition containing salvianolic acid B and pharmaceutical application thereof - Google Patents
Pharmaceutical composition containing salvianolic acid B and pharmaceutical application thereof Download PDFInfo
- Publication number
- CN104997767A CN104997767A CN201410171383.9A CN201410171383A CN104997767A CN 104997767 A CN104997767 A CN 104997767A CN 201410171383 A CN201410171383 A CN 201410171383A CN 104997767 A CN104997767 A CN 104997767A
- Authority
- CN
- China
- Prior art keywords
- salvianolic acid
- pharmaceutical composition
- group
- cell
- rat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a pharmaceutical composition containing salvianolic acid B and an application thereof. The composition contains salvianolic acid B and hydroxysafflor yellow A which are matched according to a fixed dosage to treat kidney and other diseases, wherein salvianolic acid B can be replaced with magnesium salt, potassium salt and calcium salt of salvianolic acid B. the composition can be made into a solid, liquid, gaseous or semisolid preparation. Lots of experiments confirm that the pharmaceutical composition can be used in treating kidney disease, nephrotic syndrome, cardiovascular and cerebrovascular diseases and tumour disease, etc.
Description
Technical field
The invention belongs to field of medicaments, be specifically related to a kind of pharmaceutical composition and the application thereof that contain salvianolic acid B.
Background technology
Salvianolic acid B, also known as alkannic acid B, is three molecule danshensus and the caffeinic condensation substance of a part, is a kind of depside polyol, faint yellow amorphous powder, molecular formula C36H30O16.Have and improve renal function, prevention and cure of cardiovascular disease, ischemia resisting damages, and hepatic injury, anticoagulation and antithrombotic, antiinflammatory, improves the multiple pharmacological effect such as renal function.
S-A Hydroxysafflor yellow A is the compound of single chalcone glycoside structure, it is the most effective water soluble ingredient of Flos Carthami pharmacological effect, the platelet aggregation that platelet activating factor can be suppressed to bring out and release, contestable ground suppresses the combination of platelet activating factor and platelet receptor, is the blood circulation promoting and blood stasis dispelling effective ingredient of Carthamus yellow.
Chinese patent CN101759672B discloses salvianolic acid B and is used for the treatment of application in cardiovascular and cerebrovascular disease, hepatic injury, hepatic fibrosis, pulmonary fibrosis, tumor, senescence drug, but unexposed salvianolic acid B is to the therapeutical effect of kidney disease.The technical scheme of salvianolic acid B and S-A Hydroxysafflor yellow A combined therapy nephropathy and other diseases is not more disclosed.At present, the report being used for the treatment of nephropathy and other diseases with salvianolic acid B and S-A Hydroxysafflor yellow A with fixing dosage combination is also had no.The invention discloses a kind of composition of medicine for the treatment of kidney disease, for clinical treatment kidney disease provides new method.
Summary of the invention
Confirm through lot of experiments research, pharmaceutical composition disclosed by the invention can effectively treat kidney disease, renal failure, nephrotic syndrome, tumor, cardio-cerebrovascular diseases.
The present composition contains salvianolic acid B and S-A Hydroxysafflor yellow A.
The salvianolic acid B that the present composition contains, can replace with the magnesium salt of salvianolic acid B, potassium salt, calcium salt.
Pharmaceutical composition of the present invention, by weight, containing salvianolic acid B 1-30 part and S-A Hydroxysafflor yellow A 1-30 part.Wherein, salvianolic acid B can replace with the magnesium salt of salvianolic acid B.Can also replace with the potassium salt of salvianolic acid B.Can also replace with the calcium salt of salvianolic acid B.
Salvianolic acid B in present composition composition and S-A Hydroxysafflor yellow A can be extract to obtain from the Chinese medicines such as Radix Salviae Miltiorrhizae Flos Carthami respectively, also can be obtained by the method for chemosynthesis.
Medicine composition of the present invention is preferred:
1. salvianolic acid B 1mg and S-A Hydroxysafflor yellow A 30mg.
2. salvianolic acid B 30mg and S-A Hydroxysafflor yellow A 1mg.
3. salvianolic acid B 20mg and S-A Hydroxysafflor yellow A 15mg.
4. salvianolic acid B magnesium salt 15mg and S-A Hydroxysafflor yellow A 15mg.
5. salvianolic acid B potassium salt 15mg and S-A Hydroxysafflor yellow A 15mg.
6. salvianolic acid B calcium salt 15mg and S-A Hydroxysafflor yellow A 15mg.
The present composition can make any one dosage form on pharmaceutics, comprises the preparation making solid form, liquid form, gas form or semi-solid form, optimizing injection, tablet, granule, capsule, pill or electuary etc.
The present invention has carried out experimental study to 6 groups of drug regimens, and concrete compositions is as follows:
Compositions one: salvianolic acid B 1mg and S-A Hydroxysafflor yellow A 30mg.
Compositions two: salvianolic acid B 30mg and S-A Hydroxysafflor yellow A 1mg.
Compositions three: salvianolic acid B 20mg and S-A Hydroxysafflor yellow A 15mg.
Compositions four: salvianolic acid B magnesium salt 15mg and S-A Hydroxysafflor yellow A 15mg.
Compositions five: salvianolic acid B potassium salt 15mg and S-A Hydroxysafflor yellow A 15mg.
Compositions six: salvianolic acid B calcium salt 15mg and S-A Hydroxysafflor yellow A 15mg.
Experiment one, the present invention are to the therapeutical effect of CRF rats
1. laboratory animal SD rat 170, male and female half and half, body weight 200g ± 20g, purchased from Chinese Academy of Sciences's Shanghai Experimental Animal Center.
2. Experimental agents the present invention 6 groups of composition medicine compositions, all have and are provided by Dalian Mei Lun Bioisystech Co., Ltd, are all made into 5mg/ml solution (concentration of salvianolic acid B, S-A Hydroxysafflor yellow A is identical with compositions three) with distilled water before experiment.
3. experimental technique is got SD rat and is taken out 15 immediately as blank group, and all the other rat adaptabilities feed 3 days.Except blank group, all the other rats 2.5% adenine suspension presses 250mg/kg/ days gavages, continuous gavage gives 3 weeks, during the renal failure phenomenons such as serum urea nitrogen to appear, creatinine rising, satisfactory rat is divided into immediately model group, compositions one to six group.Compositions one to six group respectively gavage gives relative medicine 10ml/kg, and blank group and model group gavage give isopyknic distilled water, daily once, and successive administration 4 weeks.After last administration 24h, abdominal aortic blood, measures serum urea nitrogen, creatinine, sero-abluminous content and each index of hemorheology, dissects kidney and carries out pathological section, basis of microscopic observation pathological change.
4. Testing index
(1) serum urea nitrogen, creatinine and sero-abluminous content is measured
(2) blood examination
(3) pathological examination
5. experimental result
(1) the present invention is on chronic kidney hypofunction rat model serum urea nitrogen, creatinine and sero-abluminous impact.In table 1.
Table 1 the present invention is on CRF rats serum urea nitrogen, creatinine and sero-abluminous impact
Note: each group compares with model group
*p<0.05,
*p<0.01
Result shows: blank group compares blood urea nitrogen with model group and creatinine is obviously lower, serum albumin is obviously higher, and have significant difference, after showing modeling, major injury is caused to rat, obviously reduce through the treatments of 4 weeks each administration group rat blood urea nitrogen and creatinine, serum albumin obviously raises, and has significant difference (p<0.05 or p<0.01).
(2) the present invention is on the hemorheological impact of CRF rats.In table 2.
Table 2 the present invention is on the hemorheological impact of CRF rats
Note: each group compares with model group
*p<0.05,
*p<0.01
Result shows: blank group compares whole blood viscosity with model group, plasma viscosity and packed cell volume are all obviously lower, and have significant difference, after showing modeling, major injury is caused to rat, through the treatments of 4 weeks each administration group rat whole blood viscosity, plasma viscosity and packed cell volume all obviously reduce, and have significant difference (p<0.05 or p<0.01).
(3) HE dyeing basis of microscopic observation result
Blank group: glomerule and renal tubules clear, structure is normal, has no pathological change; Model group: glomerule atrophy, renal tubules is obviously expanded, and proximal convoluted tubule and Distal convoluted tubule epithelial cell all have obvious cloudy swelling and degeneration to occur, renal interstitial proliferation of fibrous tissue, and have chronic inflammation cellular infiltration; Each administration group: glomerule is slightly congested, structure no abnormality seen, renal tubules has mild dilation, without obvious cell infiltration.
6. conclusion The results confirms, each administration group all has therapeutical effect preferably to chronic kidney hypofunction, is in particular in and improves serum creatinine, blood urea nitrogen, serum albumin, each index of hemorheology and pathological characteristics aspect.
Experiment two, the present composition are to brightic therapeutical effect
1. laboratory animal SD rat 120, male and female half and half, body weight 180-220g, purchased from Chinese Academy of Sciences's Shanghai Experimental Animal Center.New Zealand white rabbit 8, purchased from Xi'an Di Lepu bio-resource exploitation company limited.
2. Experimental agents the present invention 6 groups of composition medicine compositions, all have and are provided by Dalian Mei Lun Bioisystech Co., Ltd, are all made into 5mg/ml solution (concentration of salvianolic acid B, S-A Hydroxysafflor yellow A is identical with combination three) with distilled water before experiment.
3. experimental technique
(1) prepare rabbit anti-rat chest cell serum and get aseptic SD rat 6, put to death, carefully win rat chest gland and liver.Hepar siccatum is made stand-by after liver PBS wash buffer is clean; Separately thymus is placed in PBS buffer, rinse 2-3 time, careful separation, the lymph node removing its surface and blood vessel, put on 200 order rustless steel mesh screens, scratch thymus gently with dissecting needle to dissociate thymocyte cell, use PBS wash buffer, collect thymus cell suspension, centrifugal 10min, with PBS buffer recasting 2 × 10
7the thymus cell suspension of/ml, the thymus cell suspension of 1:2 mixing by volume and Freund's complete adjuvant, fully mix, using mixed suspension as rat chest cell immunizing antigen liquid.By rat chest cell immunizing antigen liquid multi-point injection in 8 New Zealand white rabbit dorsal sc, every rabbit injection 3ml.Routine is raised after 2 weeks, rabbit ear edge intravenous injection 2 × 10
7the thymus cell suspension of/ml, often only injects 1.5ml.After 7d, heart extracts rabbit blood, collects rabbit anteserum.Surveying the anti-rat chest cell serum titer of anti-rabbit by immunodiffusion method is 1:160-1:320.The anti-rat chest cell serum of rabbit in 56 DEG C, after 30min deactivation, respectively with individual rat hepar siccatum absorption to remove non-specific antibody, the centrifugal 30min of room temperature, discards hepar siccatum, and the anti-rat chest cell serum of collection rabbit ,-20 DEG C save backup.
(2) healthy SD rat 110 is got in the preparation of chronic glomerulonephritis rat model, and after adaptability feeds 3 days, collect urine, detect urine protein, result is feminine gender.Be divided into Normal group, model group, compositions one to six group immediately, often organize 10.Except rats in normal control group tail vein injection 2ml normal saline, all the other group rat disposable tail vein injection rabbits anti-rat chest cell serum 2ml.
(3) medication and the anti-rat chest cell serum of testing index injection rabbit are after 6 days, compositions one to six group respectively gavage gives relative medicine 10ml/kg, blank group and model group gavage give isopyknic distilled water, daily once, and successive administration 4 weeks.Last administration is after 24 hours, and abdominal aortic blood, measures IL-6, IL-8 and TNF-alpha levels respectively, dissects kidney, carries out pathology investigation.
4. result
(1) the present invention is on the impact of chronic glomerulonephritis rat blood serum IL-6, IL-8 and TNF-α
Table 3 the present invention is on the impact of chronic glomerulonephritis rat blood serum IL-6, IL-8 and TNF-α
Note: each group compares with model group
*p<0.05,
*p<0.01
Result shows: model group rats blood serum IL-6, IL-8 and TNF-alpha levels compared with normal matched group significantly raise (P<0.01), shows modeling success.Medicine group rat blood serum IL-6, IL-8 and TNF-alpha levels of the present invention is lower than model group (P<0.05 or P<0.01), medicine group of the present invention can reduce IL-6 contents level, shows that each administration group all can improve serum cytokines to a certain extent.
(2) pathological examination rats in normal control group glomerule profile, clear in structure, form is normal; Model group rats renal tubules obvious tumefaction, have hyperemia, tube chamber narrows, and the visible albumen of part is tubular, and glomerular volume increases, and visible inflammatory cell infiltrates; Each administration group Renal Glomeruli In Rats structure shows no obvious abnormalities, and glomerule capillary tube has slight swelling, and basement membrane slightly thickens, and cell infiltration is not obvious.
5. conclusion experimental result confirms, each administration group all has therapeutical effect preferably to chronic glomerulonephritis rat, is in particular in and reduces blood inflammatory cytokines levels in non-diabetic and improve pathological characteristics aspect.
Experiment three, investigation medicine of the present invention are to the therapeutical effect of hypertensive nephropathy
1. laboratory animal spontaneous hypertensive rat 110, male and female half and half, body weight 180-220g, purchased from Chinese Academy of Sciences's Shanghai Experimental Animal Center.
2. Experimental agents the present invention 6 groups of composition medicine compositions, all have and are provided by Dalian Mei Lun Bioisystech Co., Ltd, are all made into 5mg/ml solution (concentration of salvianolic acid B, S-A Hydroxysafflor yellow A is identical with combination three) with distilled water before experiment.
3. experimental technique
Spontaneously hypertensive rat urine microalbumin to be measured is that spontaneously hypertensive nephropathy model copies successfully when being 20-200mg/L, reject defective rat, be divided into compositions one to six group at random, salvianolic acid B group and S-A Hydroxysafflor yellow A group, separately get 10 as matched group.Each administration group gavage gives relative medicine 0.5ml/10g, and matched group gives isopyknic distilled water, and every day is administered once, successive administration 4 weeks.
4. Testing index
4.1 measure blood pressure.Before administration, measure the tail vein systolic pressure under rat waking state, at the end of experiment, again measure the systolic pressure of rat tail vein, and each survey is averaged for three times.
4.2 measure microdose urine protein in each group of rat urine, urine β
2microglobulin.Collect 12h urine before experiment terminates, fasting during collecting urine, can't help water.
The content of serum creatinine and blood urea nitrogen in 4.3 mensuration blood.Heart extracting blood at the end of experiment, the automatic clinical chemistry analyzer produced with Jinan Chinese prescription Medical Devices Co., Ltd. measures serum creatinine and blood urea nitrogen.
5 experimental results
5.1 compositionss on the impact of spontaneously hypertensive nephrotic rats blood pressure, in table 4.
Table 4 present composition is on the impact of spontaneously hypertensive nephrotic rats blood pressure before and after experiment
Note: compare with matched group
*p ﹤ 0.05
*p ﹤ 0.01
Experimental result shows: at the end of experiment, the obvious reduction compared with matched group of each administration group rat blood pressure, and has significant difference (p<0.01).Show that the blood pressure of pharmaceutical composition of the present invention to essential hypertension nephrotic rats has certain reducing effect.
5.2 the present invention are to microdose urine protein, urine β in essential hypertension nephrotic rats urine
2the impact of microglobulin content, in table 5.
Table 5 pair hypertensive nephropathy rat urine microdose urine protein, urine β
2the impact of microglobulin content
Note: compare * P ﹤ 0.05**P ﹤ 0.01 with matched group
Experimental result shows: pharmaceutical composition of the present invention obviously can lower the content of hypertensive nephropathy rat urine microalbumin and urinal beta2 microglobulin, and comparing with blank group has significant difference (p<0.01).Show that the kidney of pharmaceutical composition of the present invention to essential hypertension nephrotic rats has certain protective role.
5.3 the present invention on the impact of serum creatinine and blood urea nitrogen in essential hypertension nephrotic rats blood, in table 6.
Table 6 the present invention is on the impact of essential hypertension nephrotic rats serum creatinine and blood urea nitrogen
Note: compare * P ﹤ 0.05**P ﹤ 0.01 with model group
Result shows: pharmaceutical composition of the present invention obviously can lower the content of hypertensive nephropathy rat serum creatinine and blood urea nitrogen, and comparing with blank group has significant difference (p<0.01).Show that the kidney of pharmaceutical composition of the present invention to essential hypertension nephrotic rats has certain protective role.
The antitumor action of experiment four, investigation medicine of the present invention
1. laboratory animal BALB/C white mice 130, male and female half and half, body weight 18-22g, purchased from Chinese Academy of Sciences's Shanghai Experimental Animal Center.
2. Experimental agents the present invention 6 groups of composition medicine compositions, all have and are provided by Dalian Mei Lun Bioisystech Co., Ltd, are all made into 5mg/ml solution (concentration of salvianolic acid B, S-A Hydroxysafflor yellow A is identical with combination three) with distilled water before experiment.Hepatoma cells strain H22 is so kind as to give by ShanXi Chinese Medicine Academy pharmaceutical research room.
3. experimental technique
Set up tumor model and carefully extract from planting Mus intraperitoneal the ascites inoculating H22 cell strain out, transfer is inoculated into another mouse peritoneal, goes down to posterity three times.Get inoculation H22 cell strain and the mice of three times of going down to posterity, 1-2ml milk shape, ascites compared with thickness is gone out with 5ml syringe pump under aseptic condition, first with 0.4% trypan blu e dyeing, cell counting count board, meter living cell rate >90%, then adjusts tumor cell concentration for 1.0 × 10 with the dilution of sterilizing D-Hanks liquid
7individual/ml.Mix up the tumor cell of concentration at all the other mice right fore axillary fossas and subcutaneous vaccination, 0.15ml/ only.
Solid tumor mice, after 72 hours, is divided into 10 groups by medication Modling model at random, i.e. matched group, compositions one to six group, often organizes 10.Each administration group gavage gives relative medicine 0.5ml/10g, and matched group gives isopyknic distilled water, once a day, and successive administration 2 weeks.Record dead mouse number every day, and weigh different dosing group Mouse Weight.
During antitumor activity evaluation administration, every day weighs the weight of animals, puts to death animal after last administration 48h, peels off tumor, weighs, be placed in 10% formalin solution fixing after, carry out pathological section.
Calculate the suppression ratio of drug on tumor growth as follows.The average tumor of inhibition rate of tumor growth=(matched group average tumor weight-administration group average tumor weight)/matched group heavy × 100%.
4. experimental result
Medicine anti-tumor in vivo Activity Results of the present invention is as following table.
Table 7 anti-tumor in vivo activity experiment result
Note: each group compares with matched group
*p<0.05,
*p<0.01
Experimental result shows: different dosing group obvious Tumor suppression compared with matched group is active, all has significant difference (P<0.05), can find out that the suppression degree of each group of drug on tumor is best with prescription three.
5. conclusion drug on tumor of the present invention has inhibitory action, can be used for the treatment of tumor disease.
Experiment five, medicine of the present invention are to the protective effect of vascular endothelial cell
1. experiment material human umbilical vein endothelial cell strain (heart injuries) is purchased from Bai Li bio tech ltd, Shanghai; DMEM high glucose medium, hyclone are all purchased from Gibco company.MDA, SOD test kit builds up biological company limited purchased from Nanjing; H
2o
2be purchased from Tianjin Ke Miou chemical reagent company limited; Pancreatin, tetrazole orchid (MTT) purchased from American SIGMA company.
2. Experimental agents the present invention 6 groups of composition medicine compositions, all have and are provided by Dalian Mei Lun Bioisystech Co., Ltd, are all made into 5mg/ml solution (concentration of salvianolic acid B, S-A Hydroxysafflor yellow A is identical with combination three) with distilled water before experiment.
3. experimental technique
Human umbilical vein endothelial cell is placed in the RPMI-1640 being mixed with 2mmol/L L-glutaminate, 100 μ g/ml heparin, 100U/ml penicillin, 30 μ g/ml endothelial cell growth factor (ECGF) and 10% hyclone by cell culture, in 37 DEG C, 5%CO
2cultivate in the cell culture incubator of saturated humidity.When Growth of Cells merge to 80% time, pour out old culture medium, with PBS liquid fine laundering cell 2 ~ 3 times, then add about 1ml 0.125% pancreatin, to 37 DEG C, 5%CO
2incubator hatches 2min, when seeing under mirror that cell shrinkage becomes circle, intercellular substance increases, inhales and abandons pancreatin, adds complete culture solution containing 10% hyclone to stop the effect of pancreatin, repeatedly blows and beats cell gently, make it to come off into cell suspension from bottle wall with suction pipe.Cell counting, adjustment cell density is 1 × 10
5individual/ml, is inoculated in 96 orifice plate every hole 100 μ l, is placed in 37 DEG C, 5%CO
2cultivate under condition.After about 24h, for experiment.
Set up H
2o
2induction human umbilical vein endothelial cell damage model vascular endothelial cell is with 10
4individual/hole is inoculated in 96 well culture plates.With serum-free medium by H
2o
2be made into 0,75,150,300,600 μm of ol/L dosage group, add in 96 orifice plates respectively, every hole 100 μ l, act on 12 respectively, 24, after 48h, discarded by supernatant, every hole adds 100 μ l culture medium and 20 μ lMTT (5g/L) act on 4h, supernatant is discarded, every hole adds 150 μ l distilled water, measures cell absorbance (A) under 15min, 570nm microplate reader that microtiter shaker vibrates.Cell inhibitory rate %=(blank group absorbance-respectively organize absorbance) (A)/blank group absorbance (A) × 100%.
Medication by cell with 2 × 10
5individual/hole is inoculated in 6 orifice plates, and experiment is divided into 9 groups, Normal group: every hole gives 2ml serum-free medium; Model group: it is 300 μm of ol/LH that every hole gives 2ml final concentration
2o
2, effect 24h; Prescription one to six group of the present invention: giving 2ml final concentration is 50mg/ml relative medicine, after hatching 4h, giving 2ml final concentration is 300 μm of ol/L H
2o
2effect 24h.Detect the content of SOD, MDA in cell: each group of cell is collected in digestion, often group adds 1ml PBS, take the method (-80 ° of refrigerator 15min, room temperature 20min so repeat 5 times) of multigelation, to cell breakage, content flows out, the centrifugal 15min of 3000r/min, draws supernatant, carry out BCA protein quantification, then carry out the assay of MDA, SOD by test kit description.
4. experimental result
The protective effect that medicine of the present invention damages people's vein blood vessel, in table 8
Table 8 medicine of the present invention is on the impact of people's vein blood vessel SOD, MDA
Note: each group compares with model group
*p<0.05,
*p<0.01
Experimental result shows: each administration group comparatively model group SOD activity raises, and MDA content declines, and has statistical significance (P<0.05 or P<0.01).
5. conclusion experiment proves that prescription of the present invention can improve impaired vein endothelial cell, and prompting may be used for treatment heart and brain cardiovascular and cerebrovascular disease.
Specific embodiment
Embodiment 1
Get salvianolic acid B 6g, S-A Hydroxysafflor yellow A 1.2g, then inject and be diluted with water to 500ml, filter, add water for injection to 800ml, adjust ph, to 6.5-7.0, injects and is diluted with water to 1000ml, filters with 0.22 μm of microporous filter membrane, subpackage, sterilizing, obtains injection.
Embodiment 2
Get salvianolic acid B 600g, S-A Hydroxysafflor yellow A 120g, Portugal's first ammonia and arginine are appropriate, add water for injection and are diluted to 5L, and stir until dissolve, filter, filtrate adjust pH, to 5.0-7.0, carries out fine straining with 0.22 μm of microporous filter membrane; Get mannitol to inject in right amount and be mixed with solution with water, mix with above-mentioned filtrate, filter with 0.22 μm of microporous filter membrane, inject and be diluted with water to 10L, by the dosage subpackage of unit formulation 10ml, lyophilization, obtains lyophilized powder.
Embodiment 3
Get salvianolic acid B 200g, S-A Hydroxysafflor yellow A 40g, pre-paying starch, micropowder silica gel, magnesium stearate, Pulvis Talci is appropriate, after crossing 80 mesh sieves respectively, mixs homogeneously, add appropriate adhesive and make soft material with medicated powder, and granulate, granule is in 60 DEG C of dryings.Add mix homogeneously after micropowder silica gel, magnesium stearate and Pulvis Talci, be pressed into 1000.
Embodiment 4
Get salvianolic acid B 200g, S-A Hydroxysafflor yellow A 40g, pre-paying starch, micropowder silica gel, magnesium stearate, Pulvis Talci is appropriate, and after crossing 80 mesh sieves respectively, Homogeneous phase mixing, adds appropriate adhesive and make soft material, granulates; Granule is 60 DEG C of dryings.Add carboxymethylstach sodium, micropowder silica gel, magnesium stearate and Pulvis Talci mix homogeneously, encapsulated, make 1000.
Embodiment 5
Get salvianolic acid B 1200g, S-A Hydroxysafflor yellow A 240g, pre-paying starch, micropowder silica gel, magnesium stearate, Pulvis Talci is appropriate, then it is appropriate to add aspartame, makes soft material, granulates, after 60 DEG C of dryings, detect qualified after, be sub-packed in medicinal polyethylene plastic bag, every bag of 5g, altogether make 1000 bags.
Claims (9)
1. treat a pharmaceutical composition for kidney disease, it is characterized in that: by weight, containing salvianolic acid B 1-30 part and S-A Hydroxysafflor yellow A 1-30 part.
2. treat the pharmaceutical composition of kidney disease according to claim 1, it is characterized in that: salvianolic acid B can replace with the magnesium salt of salvianolic acid B.
3. treat the pharmaceutical composition of kidney disease according to claim 1, it is characterized in that: salvianolic acid B can replace with the potassium salt of salvianolic acid B.
4. treat the pharmaceutical composition of kidney disease according to claim 1, it is characterized in that: salvianolic acid B can replace with the calcium salt of salvianolic acid B.
5. the application of the arbitrary described pharmaceutical composition of claim 1-4 in the medicine for the preparation for the treatment of kidney disease.
6. application according to claim 5, is characterized in that: kidney disease is renal failure, nephrotic syndrome, hypertensive nephropathy.
7. the application of the arbitrary described pharmaceutical composition of claim 1-4 in the medicine for the preparation for the treatment of tumor.
8. the arbitrary described pharmaceutical composition of claim 1-4 is for the preparation of the application in the medicine of Cardiovarscular.
9. according to the pharmaceutical composition of the arbitrary described treatment kidney disease of claim 1-4, it is characterized in that: said composition is the preparation of solid form, liquid form, gas form or semi-solid form.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410171383.9A CN104997767A (en) | 2014-04-25 | 2014-04-25 | Pharmaceutical composition containing salvianolic acid B and pharmaceutical application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410171383.9A CN104997767A (en) | 2014-04-25 | 2014-04-25 | Pharmaceutical composition containing salvianolic acid B and pharmaceutical application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104997767A true CN104997767A (en) | 2015-10-28 |
Family
ID=54370812
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410171383.9A Pending CN104997767A (en) | 2014-04-25 | 2014-04-25 | Pharmaceutical composition containing salvianolic acid B and pharmaceutical application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104997767A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107582547A (en) * | 2016-07-06 | 2018-01-16 | 成都普睿法药物研发有限公司 | A kind of pharmaceutical composition for being used to treat cardiovascular and cerebrovascular disease |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1660266A (en) * | 2004-12-15 | 2005-08-31 | 咸阳步长医药科技发展有限公司 | Combination of oral medication for treating cardiovascular and cerebrovascular diseases and preparation method |
| CN1736375A (en) * | 2003-08-28 | 2006-02-22 | 北京贤达通科技有限公司 | A pharmaceutical composition and application thereof in preparation of medicine for preventing or treating cerebrovascular and cardiovascular disease |
| CN101879155A (en) * | 2007-12-04 | 2010-11-10 | 哈药集团中药二厂 | Method for preparing dan hong for injection |
-
2014
- 2014-04-25 CN CN201410171383.9A patent/CN104997767A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1736375A (en) * | 2003-08-28 | 2006-02-22 | 北京贤达通科技有限公司 | A pharmaceutical composition and application thereof in preparation of medicine for preventing or treating cerebrovascular and cardiovascular disease |
| CN1660266A (en) * | 2004-12-15 | 2005-08-31 | 咸阳步长医药科技发展有限公司 | Combination of oral medication for treating cardiovascular and cerebrovascular diseases and preparation method |
| CN101879155A (en) * | 2007-12-04 | 2010-11-10 | 哈药集团中药二厂 | Method for preparing dan hong for injection |
Non-Patent Citations (5)
| Title |
|---|
| 刘慧: "丹红注射液对慢性肾衰合并心衰患者心肾功能的影响", 《按摩与康复医学》 * |
| 张蕾等: "丹参红花有效部位配伍对大鼠心肌缺血/再灌注损伤的保护作用", 《中国实验方剂学杂志》 * |
| 胡长安等: "丹红注射液治疗老年高血压肾损害52例", 《浙江中医杂志》 * |
| 舒劲松: "丹红注射液对大鼠肾病综合症模型影响的实验研究", 《湖北中医杂志》 * |
| 郑瑾等: "丹红注射液促肝癌细胞凋亡及NDRG2表达的初步研究", 《山西医科大学学报》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107582547A (en) * | 2016-07-06 | 2018-01-16 | 成都普睿法药物研发有限公司 | A kind of pharmaceutical composition for being used to treat cardiovascular and cerebrovascular disease |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105012334A (en) | Medicinal composition for treating renal diseases and pharmaceutical use of medicinal composition | |
| CN105859904A (en) | Achyranthes aspera stem and/or leaf and/or root extract and extraction method and application thereof | |
| Liang et al. | Effect of Chinese herbal compound on liver fibrosis in rabbits with schistosomiasis by B-ultrasound | |
| CN101926815B (en) | Paeoniflorin and glycyrrhetinic acid composition and preparation method and application thereof | |
| CN103446577A (en) | Medicine composition for preventing and treating arthritis and application thereof | |
| CN105412318A (en) | Traditional Chinese medicine fumigation and washing bag soaking agent for treating knee osteoarthritis and preparation method thereof | |
| CN105012283A (en) | Medicine composition containing parietic acid and pharmaceutical purpose of medicine composition | |
| CN104997855A (en) | Pharmaceutical composition containing total anthraquinone in rheum and total salvianolic acids and pharmaceutical application thereof | |
| CN104997767A (en) | Pharmaceutical composition containing salvianolic acid B and pharmaceutical application thereof | |
| CN104997764A (en) | Pharmaceutical composition containing salvianolic acid B and tanshinol and pharmaceutical application thereof | |
| CN103893283A (en) | Traditional Chinese medicine composition for treatment of chronic renal diseases and chronic renal failure and its preparation method and use | |
| CN105012386A (en) | Medicine composition containing astragalus polysaccharide and pharmaceutical purpose of medicine composition | |
| CN104997802A (en) | Pharmaceutical composition containing calycosin and pharmaceutical application thereof | |
| CN105012411A (en) | Medicinal composition for treating kidney diseases and pharmaceutical application thereof | |
| CN105535011A (en) | Applications of mushroom mycelium polysaccharides | |
| CN111588762B (en) | Medicine for treating thromboangiitis obliterans, preparation method and content determination method | |
| CN103705772B (en) | Chinese medicine composition that a kind of antiinflammatory protects the liver and preparation method thereof | |
| CN1951380A (en) | Medical usage of salvianolic acid B salt and total salvianolic acid | |
| CN104997856A (en) | Pharmaceutical composition containing total anthraquinone in rheum and pharmaceutical application thereof | |
| CN103893286B (en) | It is a kind of to treat Chinese medicine preparation of chronic renal disease and preparation method thereof | |
| CN105012412A (en) | Medicinal composition for treating kidney diseases and pharmaceutical use of medicinal composition | |
| CN101306091B (en) | Use of prince feather and fleabane combination in preparing medicament for treating kidney disease | |
| CN103751583A (en) | Traditional Chinese medicine composition for being diuretic and protecting liver and preparation method of composition | |
| CN100382817C (en) | Collateral channels clearing arthralgia dredging prescription for treating rheumatoid arthritis and its preparing process | |
| CN104688723A (en) | Application of anhydroicaritin in preparation of medicine for treating anaemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20151028 |
|
| RJ01 | Rejection of invention patent application after publication |